MOUNTAIN VIEW, Calif.,
Feb. 24, 2015 /PRNewswire/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is
presenting at the 27th Annual ROTH Conference, to be
held March 8-11, 2015 at the
Ritz-Carlton Hotel in Laguna
Niguel, CA.
Thomas B. King, Alexza's
President and CEO, will be giving the corporate presentation on
Tuesday, March 10 at 2:30 p.m. Pacific
Time. The webcast of the presentation may be accessed
from the Investors section of the Alexza website at
www.alexza.com. A replay will be available for 30 days,
beginning approximately 24 hours after the presentation.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development, and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE®, Alexza's first commercial product, is based
on the Staccato system and has been approved for sale by the
U.S. Food and Drug Administration, the European Commission,
and in several Latin American countries. ADASUVE is currently
being marketed in eleven countries.
Teva Pharmaceuticals USA, Inc.,
a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza's
commercial partner for ADASUVE in the United States. Grupo
Ferrer Internacional SA is Alexza's commercial partner for ADASUVE
in Europe, Latin America, and the Commonwealth of
Independent States countries.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc. For more
information, please visit www.alexza.com.
Safe Harbor Statement
The conference presentation
contains forward-looking statements that involve significant risks
and uncertainties. Any statement describing the Company's
expectations or beliefs is a forward-looking statement, as defined
in the Private Securities Litigation Reform Act of 1995, and should
be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the
process of developing and commercializing drugs, including the
ability for Teva and Ferrer to effectively and profitably
commercialize ADASUVE, estimated product revenues and royalties
associated with the sale of ADASUVE, the adequacy of the Company's
capital to support the Company's operations, and the Company's
ability to raise additional funds and the potential terms of such
potential financings. The Company's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its
results to differ materially from those expressed or implied by
such forward-looking statements. These and other risks concerning
Alexza's business are described in additional detail in the
Company's Annual Report on Form 10-K for the year ended
December 31, 2013 and the Company's
other Periodic and Current Reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Logo- http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alexza-pharmaceuticals-announces-presentation-at-the-27th-annual-roth-conference-300039878.html
SOURCE Alexza Pharmaceuticals, Inc.